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Abstract 
In common with global trends, the number of individuals with Type 2 diabetes in the 
UK is rising, driven largely by obesity. The increasing prevalence of younger 
individuals with type 2 diabetes is of particular concern, due to the accelerated 
course of diabetes-related complications that is observed in this population. The 
importance of good glycaemic control in the prevention of microvascular 
complications of diabetes is widely accepted and there is a growing body of evidence 
to support a benefit in the reduction of cardiovascular events in the long-term. 
Despite the importance of maintaining a healthy weight for the prevention of type 2 
diabetes; the results from trials of lifestyle intervention strategies to reduce body 
weight have been disappointing. New glucose-lowering agents offer some promise in 
this regard, offering an opportunity to combat the dual burden of hyperglycaemia and 
obesity simultaneously. The timing and appropriate choice of glucose lowering 
therapy has never been more complex owing to rising prevalence in the young, 
concomitant obesity in some 90% of adults with type 2 diabetes and an ever 
increasing range of therapeutic options. The present review evaluates performance 
measures specific to weight and glycaemic control in type 2 diabetes in the UK using 
data from the Quality and Outcomes Framework in England and Wales, and Scottish 
Diabetes Survey. Potential barriers to improvement in standards of care for people 
with type 2 diabetes are considered, including patient factors, clinical inertia and the 
difficulties in translating therapeutic guidelines into everyday clinical practice.  
 
 
 
  
Introduction 
 
The publication of the updated National Institute for Health and Care Excellence 
(NICE) guidance for the management of type 2 diabetes [1] is a timely prompt to 
review opportunities to improve diabetes care. These guidelines have incorporated 
some recent therapeutic advances and have focused mainly on glycaemic indicators 
with regard to drug choices. By contrast the American Diabetes Association (ADA) 
[2] and International Diabetes Federation (IDF) [3] guidelines emphasise other 
factors to be considered in the choice of diabetes medicines in order to improve care. 
Due to the complexities of the condition, the range of drug classes to be considered, 
and patient and prescriber treatment considerations, the realities of clinical practice 
are indeed complex.  
 
Efforts to curb the inevitable rise in complications associated with diabetes have led 
to a systematic evaluation of quality of care in England and Wales. Since 2004, 
disease specific indicators for both processes of care and treatment targets have 
been assessed through the pay for performance, Quality and Outcomes Framework 
(QOF). This review aims to evaluate contemporary care in the UK based on 
performance measures for glycaemic control and body-mass index. Particular 
emphasis will be placed on guidance from NICE that is most relevant to UK practice, 
and on which the QOF measures are based. In addition, barriers to ‘gold standard” 
care, and opportunities to improve existing standards, will be considered from a UK 
perspective. 
 
Importance of glycaemic control 
 
There is established evidence confirming that improved blood glucose control results 
in substantial benefits in diabetes microvascular disease outcomes,[4-6] reducing 
disability in diabetes mediated by end organ damage to the eyes, kidneys and 
nerves. Diabetes is also associated with significant premature mortality, and around 
half of individuals with type 2 diabetes will die prematurely as a result of 
cardiovascular disease (CVD) [7]. The evidence for a reduction in CVD with intensive 
glucose control is less convincing when compared with microvascular outcomes. 
However, long-term follow-up among individuals with both type 1 [8] and type 2 
diabetes [9, 10] randomised to strict glycaemic control has suggested that 
cardiovascular events are reduced when compared with standard treatment arms.  
 
The 10-year extension post intervention in The UK Prospective Diabetes Study 
(UKPDS) reported a significant 15% reduction in myocardial infarction (MI) and 13% 
reduction in all-cause mortality among patients with type 2 diabetes receiving 
intensive therapy (sulphonylurea-insulin) compared to controls [9]. In the cohort of 
overweight patients receiving metformin, intensive therapy was associated with even 
greater reductions in the risk of MI (33%) and death (27%) [11]. At the conclusion of 
the interventional study, conventional treatment and intensive therapy corresponded 
with HbA1c levels of 7.9% and 7.0%, respectively. Importantly, the outcome benefits 
described above produced a legacy effect after a further 10-year extension, where no 
significant differences in glycaemic control were observed between study groups.  
 
In addition to glycaemic control, subsequent trials have evaluated other risk factors 
and shown that effective control of blood pressure and cholesterol in type 2 diabetes 
reduces rates of CVD and mortality [12, 13].  
 
Importance of weight control 
 
A recent report from Public Health England suggests that 90% of adults with type 2 
diabetes are overweight or obese [14]. The relationship between BMI in type 2 
diabetes and outcome has been extensively scrutinised. Reports of an obesity 
paradox in type 2 diabetes where raised BMI is associated with reduced mortality 
[15, 16] have been criticised for being underpowered or failing to adequately adjust 
for smoking history (associated with both reduced BMI and mortality). The obesity 
paradox was challenged by an analysis of pooled data from two large observational 
cohort studies including 11,427 patients with incident type 2 diabetes [17]. A direct 
linear relationship between mortality and BMI was observed among individuals who 
had never smoked and a J-shaped association among those with a history of 
smoking, where smoking attenuated the benefit of a low BMI. BMI data in this study 
were collected before, or shortly after, a diagnosis was made. A population-based 
cohort study in the UK supported the notion that both smoking and obesity contribute 
to the risk of all-cause mortality in type 2 diabetes. In this study a U-shaped curve 
associated with BMI and mortality was found; the hazard ratios for those with a BMI 
of 35-54 kg/m2 and 15-19 kg/m2 were 1.43 (1.28-1.59) and 1.38 (1.18-1.61), 
respectively (Figure 1) [18]. These data underscore the importance of maintaining a 
healthy body weight from the early stages of type 2 diabetes.  
 
Obese people are seven times more likely to develop type 2 diabetes compared to 
those with a healthy BMI (20-25 kg/m2), with a threefold increased risk among those 
who are overweight [19]. Beyond incident type 2 diabetes, obesity is associated with 
other cardiovascular risk factors, including hypertension and, importantly, resistant 
hypertension [20, 21]. Dietary interventions in the trial setting have yielded benefits in 
both the prevention of type 2 diabetes and improvement in glycaemic and blood 
pressure control among individuals with existing type 2 diabetes [22, 23]. Similarly, 
weight loss achieved through bariatric surgery has shown promise for patients with 
obesity and uncontrolled diabetes in terms of glycaemic control,[24] and metabolic 
changes observed postoperatively suggest there may be glycaemia benefits 
independent of weight loss per se [25].  
 The impact of lifestyle-mediated weight loss on cardiovascular outcomes in type 2 
diabetes has also been investigated, most notably in the Look AHEAD study, which 
reported improved glycaemic control and CVD risk factor profile among participants 
randomised to intensive lifestyle intervention. This translated into clinically significant 
weight loss (8.6% of initial weight versus 0.7% among controls) at one year [26]. 
Despite sustained positive effects associated with intensive lifestyle intervention 
including the need for fewer glucose-lowering drugs and increased likelihood of 
achieving HbA1c levels <7% (53 mmol/mol) [27], the 10-year follow-up study showed 
no significant difference between groups for cardiovascular morbidity and mortality 
[28]. The spectrum of glucose lowering medications in type 2 diabetes includes those 
that promote weight gain (insulin, sulphonylureas and thiazolidinediones) and offer 
weight neutrality (metformin and dipeptidyl peptidase-4 inhibitors). The availability of 
novel agents associated with weight loss (glucagon-like peptide-1 receptor agonists 
and sodium-glucose co-transporter 2 inhibitors) offer promise for combatting obesity 
in type 2 diabetes as part of a multifactorial approach including good lifestyle.  
 
Economic considerations 
 
The burden of diabetes to the NHS is thought to represent around 5-10% of the 
overall budget and is projected to account for around 17% in 2035 [29-31], with 
current direct costs attributable to type 2 diabetes estimated at around £8.8bn [31]. A 
health economics assessment undertaken by the York Health Economics 
Consortium suggests that less than a quarter of this cost relates to the treatment and 
ongoing management of diabetes; the remainder is attributable to the treatment of 
complications of the disease [31]. Because the effects of hyperglycaemia are 
cumulative [4, 11], it seems intuitive that early implementation of evidence based 
guidance and greater achievement of glycaemic and weight targets would reduce the 
incidence of complications or, at the very least delay their onset, resulting in cost 
savings for the health service. It is entirely paradoxical; therefore, to withhold best 
practice management early in the disease trajectory of type 2 diabetes in an effort to 
curb spending, as such practice is likely to increase the incidence of complications 
that account for a disproportionate share of overall healthcare costs. Early control of 
glycaemia in the decade following diagnosis, as observed in UKPDS, can mitigate 
risk of microvascular complications and has important legacy benefits for reduction of 
cardiovascular disease in the long-term [9].  
 
Achievement of glycaemic (HbA1c) and BMI guideline targets on a population 
level 
 
Glycaemic control 
 
An estimated 3.5 million individuals in the United Kingdom have type 2 diabetes [32], 
a figure that is expected to rise to over 5.5 million by 2035 [31], driven by population 
growth, ageing and rising levels of obesity. In the past two decades in the UK, the 
proportion of younger adults below the age of 40 with newly diagnosed type 2 
diabetes has doubled [33]. Rising prevalence of young-onset diabetes will have a 
negative impact on the incidence of diabetes related complications as they are likely 
to develop at an earlier stage of life [34, 35], with implications for the individual and 
the health care authority in which they reside. Among individuals with type 2 diabetes 
in youth, higher HbA1c is associated with greater risk of complications [36], 
reinforcing the importance of optimising glycaemic control early on in the natural 
history of disease. 
 
The 2015 NICE guidance recommends an HbA1c target of 48 mmol/mol (6.5%) for 
individuals with type 2 diabetes managed by lifestyle and a single glucose-lowering 
agent (Table 1) [1]. Additional or add-on therapy is advocated when HbA1c rises to 
58 mmol/mol (7.5%) or higher with intensified monotherapy and reinforced lifestyle 
advice. At this junction, the target HbA1c is increased to 53 mmol/mol (7.0%). The 
UK National Diabetes Audit measures the effectiveness of diabetes care in England 
and Wales against NICE standards. In the most recent audit year (2014-2015), 
around 4700 primary care practices and 99 specialised services contributed data on 
1.9 million individuals with diabetes [37]. Between 2009 and 2015, between 90 and 
95% of patients with T2DM underwent HbA1c monitoring at 6 monthly intervals, of 
whom 65 to 67% achieved NICE treatment targets (applicable to that period) of ≤58 
mmol/mol (7.5%) (Figure 2). Significantly, the lowest rates of achievement were 
among patients under 40 years and those aged 40 to 64 years, and appreciable 
geographical variation in achievement of treatment targets was observed. 
 
In Scotland during the same time period, achievement of the NICE target ≤58 
mmol/mol (7.5%) ranged from 60 to 64%. Between 13% and 15% of those with type 
2 diabetes in Scotland had an HbA1c >75 mmol/mol (9.0%) [38]. This statistic is 
alarming given that UKPDS reported MI event rates of 20 per 1000 person years 
among participants with an HbA1c between 9.0 and 10.0% compared to 13 per 1000 
person years among those with good glycaemic control (HbA1c 6.0-7.0%) [39]. In 
that study, for each 1% reduction in HbA1c events rates were reduced significantly 
for diabetes-related deaths (21%), myocardial infarction (14%) and microvascular 
complications (37%). It is also significant that no lower HbA1c threshold for risk was 
observed for any endpoint (Figure 3). 
 
International comparisons 
 
UK data on achievement of HbA1c goals can be compared with the most recent 
reports based on the National Health and Nutrition Examination Survey in the US, 
where, between 2007 and 2010, 52.2% and 79.1% of participants had an HbA1c <53 
mmol/mol (7.0%) and <64 mmol/mol (8.0%), respectively [40]. Among patients in the 
Swedish National Diabetes Register with type 2 diabetes and no history of coronary 
heart disease, 78.4% achieved national guideline targets of an HbA1c <56 mmol/mol 
(7.3%) in 2008 [41]. Although not a directly comparable cohort, these European data 
would suggest that UK achievement of glycaemic goals are not among the best in 
Europe. The European Study on Cardiovascular Risk Prevention and Management in 
Usual Daily Practice (EURIKA) that collected data between 2009 and 2010 
suggested wide variation in achievement of glycaemic goals across European 
countries. Among 2046 patients with type 2 diabetes, an HbA1c of <48 mmol/mol 
(6.5%) was achieved in 36.7%, and varied between 26.0% and 48.4% between the 
12 countries that contributed patients, although numbers in each were small [42]. A 
report from the Guideline Adherence to Enhance Care (GUIDANCE) study 
conducted across 8 European countries in primary and specialist care found only 
53.6% of participants had an HbA1c <53 mmol/mol (7.0%), again with a lack of 
between-country consistency in achievement of targets [43]. 
 
Weight (BMI) control 
 
Body-mass index was also well recorded in both England and Wales, and Scotland. 
From 2009, a record of BMI was made in between 82.0 and 89.7% of individuals with 
type 2 diabetes in Scotland [38], and 83.1 to 90.9% in England and Wales [32]. The 
BMI data for Scotland in 2014 suggest that 87% of patients with type 2 diabetes were 
overweight or obese (BMI ≥25 kg/m2), over half of patients satisfied BMI criteria for 
obesity (≥30 kg/m2) and 26% of patients had severe obesity (BMI ≥35 kg/m2). 
Similarly, in 2009-2010 in England and Wales, 90% of adults with type 2 diabetes 
aged 15-54 years were overweight or obese. Consistent with findings of inferior 
glycaemic control in younger people with type 2 diabetes in the National Diabetes 
Audit, the proportion with overweight or obesity was greater among individuals aged 
16-54 years than those 55 years or older (Figure 4) [44]. 
 
Barriers to optimal care and opportunities for improvement 
 
The overall benefit of improved glycaemic control and weight reduction in type 2 
diabetes has been demonstrated definitively [45-47], yet achievement of targets on a 
population level remains poor. Suboptimal treatment and control of type 2 diabetes is 
a multifactorial issue, and the success of any strategy to overcome it will be 
predicated on an understanding of the progressive natural history of the disease and 
the ability to overcome a number of practical barriers. The progressive nature of type 
2 diabetes means an escalation of treatment is usual in order to improve glycaemic 
control and reduce complications [48]. A “one size fits all” approach is unlikely to be 
effective because disease progression results from a combination of impaired insulin 
sensitivity and beta-cell dysfunction that vary on an individual basis. Additionally 
there is a wide range in patient responses to the different drugs and drug classes 
used in diabetes [49]. The result of inadequate response to single therapy is often a 
complex prescribing pattern, which has implications for patients and physicians. The 
complexity of treatment regimen is inversely associated with adherence and [50, 51], 
in turn, poor adherence is associated with smaller reductions in HbA1c [52]. For 
physicians, interpreting and implementing clinical guidelines in the context of an 
individual patient can be a daunting prospect, further complicated by the wide range 
of treatment regimens now available. 
 
Adherence issues 
 
The World Health Organisation recognise patient non-adherence to therapies as one 
of the major barriers to improving health outcomes [53], and there are UK-based data 
to support this view in type 2 diabetes. An analysis of primary care records, that were 
adjusted for confounding factors found that non-adherence to prescribed medications 
and clinic non-attendance were independent risk factors for death from any cause 
among individuals with type 2 diabetes [54]. Barriers to adherence can result from a 
multiplicity of factors including polypharmacy, complexity of medication regimens, 
tolerability of medications including side effects such as gastrointestinal disturbance, 
weight gain and hypoglycaemia, poor knowledge of disease and cognitive 
impairment among elderly patients. Modifications to reduce the frequency of 
administration or the number of therapies are likely to improve compliance, and the 
role of fixed-dose combinations or co-administered dual therapy with reduced pill 
burden is likely to expand in this regard [55]. Reasons for non-adherence may 
change during the course of disease, but adherence is most likely to decline in the 
first six months following initiation of therapy [56]. This finding has implications for 
starting de-novo drug treatment and escalating therapy. A report evaluating 
participants with type 2 diabetes newly started on a first antihyperglycaemic 
treatment suggests poor medication adherence was associated with elevated HbA1c 
and predicted delay to intensification of therapy [57]. Patients in the highest 
adherence quartile were significantly more likely to have their regimens intensified 
during at least three years of follow up than those in the lowest quartile for adherence 
(37.4% versus 26.7%).  
 
Patient factors 
 
Fear of weight gain or hypoglycaemia, whether real or perceived, can negatively 
influence adherence to medication [58, 59]. Furthermore, individuals who are obese 
have been shown to have significantly poorer adherence than their non-obese 
counterparts with type 2 diabetes [60]. Many glucose lowering treatments are known 
to drive weight gain and observational data from the UK suggest that weight gain 
after initiating a new glucose-lowering therapy is associated with increasing primary 
care spending that results from both increased prescribing and contact with primary 
care physicians [61]. Such barriers may be overcome with the availability of glucose-
lowering therapies that offer weight neutrality or reduction, and those with reduced 
incidence of hypoglycaemia, although the benefits of these agents for adherence will 
rely on patient awareness. Where agents can successfully combine efficacy in 
HbA1c reductions and weight loss, as has been demonstrated in real world data on 
SGLT2 inhibitors and GLP-1 receptor agonists [62, 63], patients may gain positive 
reinforcement to maintain good adherence and improve lifestyle choices to promote 
further weight loss. 
 
Patient education 
 
Patient education remains a foundation of existing type 2 diabetes programmes and 
is a widely recommended strategy to improve outcome [64]. While it is indisputable 
that patient knowledge is important for several aspects of care, there are few trial 
data to support the efficacy of this approach for improvement in glycaemic control. A 
meta-analysis of 18 randomised controlled trials evaluating the effect of educational 
interventions on body weight and glycaemic control in type 2 diabetes reported 
pooled reductions in HbA1c of 0.4%, compared with control arms [65]. A more recent 
study evaluating the effectiveness of a group-based self management (X-PERT) 
programme in the UK also demonstrated modest improvements in HbA1c (-0.6%) 
when compared to a control group with type 2 diabetes attending individual 
appointments [66]. Participation was also associated with improvement in BMI (-
0.2kg/m2 vs +0.4kg/m2) and waist circumference at 14 months. Assessment of the 
diabetes education and self-management programme (DESMOND) in 731 
individuals with newly diagnosed type 2 diabetes, at 207 general practices in the UK, 
failed to demonstrate any benefit in HbA1c control in comparison with controls at 
three years [67]. Beyond the controlled trial setting, evidence is currently lacking to 
support long-term benefits of structured education.  
 
In the same way that diabetes management is increasingly tailored to a specific 
patient profile, the solutions to poor adherence should also be personalised. The 
patient-healthcare provider relationship is central to the solution and should aim to 
build trust and a greater understanding of the disease and treatment options. The 
majority of diabetes is self-managed and patients must “buy in to” a strategy to 
prolong healthy life and reduce the risks of complications. 
 
Clinical inertia 
 
Clinical inertia has been defined as a failure to intensify treatment on a timely basis 
despite inadequate treatment response. It is a phenomenon common to several 
major chronic diseases including hypertension and dyslipidaemia, as well as 
diabetes.  This difficulty in translating evidence based guidance on escalation of 
treatment into practice has been attributed to barriers at the healthcare system, 
healthcare provider and patient level [68, 69]. The magnitude of the problem is 
highlighted by the statistic that less than two thirds of patients in the UK are 
achieving even modest HbA1c targets of ≤58 mmol/mol (7.5%), as previously 
discussed. A study by Khunti et al using administrative care data on over 80,000 
individuals with type 2 diabetes in UK primary care suggests there are significant 
delays in treatment intensification following sup-optimal HbA1c control [70]. The 
mean HbA1c level at which escalation of treatment occurred was 8.7, 9.1 and 9.7% 
among individuals taking one, two or three oral antihyperglycaemic medications, 
respectively. Furthermore the median time to starting a second-line treatment for 
those poorly controlled (HbA1c > 7%) on monotherapy was 2.9 years. A further UK-
based study reported a mean gap of 7.7 years from initiation of a second or third line 
oral antihyperglycaemic agent and insulin therapy, with a mean HbA1c of around 
10% (86 mmol/mol) at the time of first insulin prescription [71]. Data from controlled 
trials indicating improvement in these outcomes translates into meaningful reductions 
in diabetes-related complications has been replicated in “real-world” data. A study 
involving over 100,000 patients registered at a general practice in the UK found the 
risk of cardiovascular events is increased when treatment escalation is delayed [72]. 
 
Given the wealth of available treatment algorithms for type 2 diabetes and the 
apparent lack of adherence to them in many cases, much of the emphasis has been 
placed on physician behaviour and education in efforts to overcome inertia and 
improve care [73-75]. This is, however, a simplistic view because physician inertia 
may also be influenced by patient-related and systematic factors [76-78]. For their 
part, health care professionals should aim to detect problems early, set realistic goals 
and promptly intervene [79]. These steps are reliant on a sound understanding of the 
available treatment options and their implementation will have significant overlap with 
systemic factors in the healthcare system in which they practice. 
 
Translating guidelines into clinical practice 
 
The introduction of incentivised payments in 2004 through QOF has arguably been 
the most significant systematic effort to drive standards in diabetes care in the UK. A 
systematic review of studies published between 1999 and 2006 found that the 
introduction of QOF incentives has led to significant improvements in both standards 
of care and major intermediary outcome measures including HbA1c [80]. These data 
are supported by a more recent study of routine administrative health data from 
practices in England which showed stepwise improvements in the proportion of 
patients achieving target HbA1c of ≤7.5% (59.1% in 2004-2005 versus 80.2% in 
2007-2008 [81]. The QOF revision in 2011/2012 that raised the threshold at which 
the HbA1c indicator was incentivised, from 53 mmol/L (7%) to 58 mmol/L (7.5%) may 
have served to increase clinical inertia around escalation of antihyperglycaemic 
therapy. Indeed, the proportion of patients achieving an HbA1c goal of <7.5% in 
England and Wales has never reached the levels of 2010/2011 since that year 
(Figure 2). 
 
Despite the overall positive influence of QOF incentives on routine monitoring, and 
modest improvements in glycaemic control that have resulted, the trend for increased 
chronic disease management in primary care and away from disease specialists has 
placed pressure on providers in terms of length and frequency of appointments, and 
the levels of knowledge expected of them. Contemporary guidelines have done little 
to simplify the complexity and volume of research on glucose lowering agents [1, 2], 
such that they may be difficult to interpret for the specialist, let alone a primary health 
care provider who must be familiar with the management of several chronic 
diseases. The flow diagrams featured in recent NICE guidance are hard to follow and 
fail to provide clear recommendations for commonly encountered patient subgroups 
[82]. When simple and accessible, use of glucose algorithms at the point of care has 
been shown to improve physician behaviour as measured by frequency of 
intensification, with subsequent improvements in glycaemic control [83]. There are 
clear roles for treatment algorithms in diabetes, as these process of care 
interventions have also been shown to reduce clinical inertia in other areas of 
medicine [84]; however, they must be accessible to the primary care providers who 
undertake the lions share of diabetes management in the UK. 
 
Timing and selection of add-on therapy 
 
There exists near universal acceptance that metformin should remain the first-line 
therapy among individuals in whom lifestyle modification is insufficient to control 
hyperglycaemia [1, 2, 64]. There is still a debate surrounding the selection of a 
second-line agent when metformin monotherapy fails to adequately control 
hyperglycaemia. It is here that the drive to individualise therapy is most relevant and 
the reason behind the complexity of many consensus guidelines. In the 2015 joint 
treatment guidelines from the European EASD and North American ADA, there are 
six drug classes to choose from when advancing to dual combination therapy, 
including sulfonylureas (SU), thiazolidinediones (TZD), dipeptidyl peptidase-4 (DPP-
4) inhibitors, GLP-1 agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors and 
insulin. The EASD/ADA position statement acknowledges that initial combination 
therapy with metformin and a second-line agent may help patients to reach target 
HbA1c quicker than sequential therapy, particularly among individuals with very high 
baseline values [2], a position echoed by the American College of Endocrinologists 
for individuals with a baseline HbA1c >7.5% [85]. This recommendation is welcome 
for the reasons outlined above and contrasts slightly with those of the recent NICE 
document which provides a different message by its suggestion of waiting until 
HbA1c rises to >58 mmol/mol (7.5%) before escalation of therapy [1].  
 
Sulfonylureas, with 60 years of clinical data, have been a mainstay of add-on therapy 
in type 2 diabetes and their combination with metformin has served as a control in 
several trials of newer agents. In a UK study using primary care data on over 25,000 
individuals with type 2 diabetes, TZDs and DPP-4 inhibitors demonstrated near 
equivalent glucose lowering effects to SUs when combined with metformin [86]. 
There are some data to support greater HbA1c lowering with the combination of 
GLP-1 receptor agonists with metformin over combinations with a DPP-4 inhibitor 
[87], although other combinations with SUs and TZDs are broadly equivalent in their 
glucose lowering effects. The newest class of agent, SGLT2 inhibitors, have fewer 
data on comparative effectiveness but appear to offer similar efficacy to other agents, 
leading to HbA1c reductions ≈0.5 – 1.0% [88, 89]. Pooled data from regulatory 
submissions and published trials suggest that SGLT2 inhibitors offer a magnitude of 
cardiovascular protection greater than might be expected by reductions in HbA1c 
alone [90, 91]. SGLT2 inhibitors work uniquely to lower the renal threshold for 
glucose, which is excreted at greater concentrations in the urine, leading to both 
lowering of blood glucose and reductions in weight owing to caloric loss. This class of 
antihyperglycaemics are likely to have the greatest role early in the disease course 
relative to other add-on therapies given that renal excretion of glucose with SGLT2 
inhibitors will be attenuated with declining eGFR, which is progressive in type 2 
diabetes [92, 93], and data to suggest they offer a longer duration of glucose 
lowering effect when compared to SUs [94], and on indirect comparison with the 
literature on DPP-4 inhibitors [95]. GLP-1 receptor agonists are the other class of 
glucose lowering drugs that promote weight loss, and there are early data to support 
reductions in cardiovascular events with these agents also [96]. They act on 
pancreatic islet cells to stimulate insulin secretion and inhibit glucagon secretion, 
while also delaying gastric emptying and promoting satiety, hence their propensity to 
promote weight loss. Real world data from the UK suggest that GLP-1 receptor 
agonists can offer greater reductions in HbA1c and improved weight control when 
compared to DPP-4 inhibitors [97], a finding that is supported by some trial evidence 
[98]. 
 
Comparative effectiveness data from the Glycemia Reduction Approaches in 
Diabetes: A Comparative Effectiveness Study (GRADE) that is expected to report in 
2020 will provide much needed long-term data on available medications when added 
on to metformin [99]. The study will randomise 5000 participants to combination 
therapy with metformin and one of four agents: glimepiride, sitagliptin, liraglutide or 
insulin glargine; unfortunately the trial does not include an SGLT2 inhibitor arm. The 
primary endpoint has been confirmed as the time to failure of glycaemic control that 
is defined as an HbA1c of 7.0% or higher. Although secondary outcomes with 
respect to hypoglycaemic episodes, weight, microvascular disease and 
cardiovascular risk factors will be monitored, the trial is primarily designed to address 
which agent provides the best long-term control of blood glucose. 
 
Conclusions 
 
Good glycaemic control is the cornerstone of any strategy to reduce the risk of 
diabetes-related complications, yet achievement of evidence based guideline targets 
in the UK is modest at best. While incentivised payments in primary practice have 
driven standards of care with respect to identifying poor HbA1c control in type 2 
diabetes, this modifiable risk is not being addressed in a timely fashion. The reasons 
for this are complex and multifactorial, involving healthcare system, physician and 
patient factors. Efforts to address suboptimal care in the UK should involve an 
emphasis shift from the management of complications to their prevention, a move 
that will have enormous health and economic implications for the better. Key 
opportunities lie in the appropriate selection of therapies for the majority of people 
with type 2 diabetes who are overweight or obese, optimising the timing of add-on 
therapies and finally, addressing issues of patient adherence.  
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Table 1. Summary of NICE and EASD guidelines for glycaemic (HbA1c) control in 
type 2 diabetes [2, 64, 82, 100] 
 
Guideline Cohort HbA1c target 
mmol (%) 
NICE CG 87 
(2009)[100] 
T2DM general target 
48 mmol/mol 
(6.5%) 
NICE NG 28 
(2015)[1] † 
T2DM managed by lifestyle and diet +/- single 
drug 
 
48 mmol/mol 
(6.5%) 
T2DM, if HbA1c level not adequately controlled 
by a single drug and rise to 58 mmol/mol 
(7.5%) or higher 
53 mmol/mol 
(7.0%)* 
T2DM, on a drug associated with 
hypoglycaemia 
53 mmol/mol 
(7.0%) 
EASD / ADA 
position statement 
2012 (update 
2015)[2, 64] 
T2DM general target 
<53 mmol/mol 
(7.0%) 
Selected patients with short disease duration, 
long life expectancy, no CV risk factors 
42-48 mmol/mol 
(6.0-6.5%) 
Selected patients with severe hypoglycaemia, 
limited life expectancy, advanced 
complications, extensive comorbidity 
58-64 mmol/mol 
(7.5-8.0%) 
 
* Intensify drug treatment 
† 
Consider relaxing all above, on case-by-case basis, for older and frail patients with multiple comorbidities. 
 
 
 
  
 
 
Figure 1. The association of BMI and all-cause mortality in type 2 diabetes 
 
Adjusted for age, gender, smoking status and duration of diabetes 
Adapted from Mulnier et al[18] 
   
 
 
 
 
Figure 2. Percentage achievement of NICE recommended HbA1c monitoring and 
treatment targets (≤58 mmol/mol) among individuals with type 2 diabetes in England, 
Wales and Scotland[1, 37, 38]  
 
*Data provided for type 1 and type 2 diabetes combined 
 
 
 
 
 
 
  
  
 
 
Figure 3. Endpoint related to diabetes: adjusted incidence rate and 95% confidence 
intervals for any endpoint related to diabetes by category of HbA1c* 
 
*Endpoint includes myocardial infarction, sudden death, angina, stroke, renal failure, lower extremity amputation or 
death from peripheral vascular disease, death from hyperglycaemia or hypoglycaemia, heart failure, vitreous 
haemorrhage, retinal photocoagulation, and cataract extraction 
Taken from Stratton et al, UKPDS 35[39] 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Weight status among adults with type 2 diabetes in England and Wales 
 
Extrapolated from data provided by the National Diabetes Audit 2009-2010[44]  
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